Market Analysis: Global Meniere's Disease Drug Market
Meniere's disease drug Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the high prevalence of hearing disorders and the lack of any approved treatment options. Rising investment in the research & development of treatments for Meniere’s disease is expected to drive the market.
Market Definition: Global Meniere's Disease Drug Market
Meniere’s disease is a disorder of inner-ear that typically affects one ear, inner ear is responsible for hearing and balance. This condition can cause vertigo, ringing in the ear (tinnitus), feeling of pressure in the ear, specific type of dizziness in which patient feel like spinning, hearing loss that comes and goes. This is a chronic condition and can lead to permanent hearing loss but treatments and lifestyle changes can help to control the symptoms.
According to the report of National Institute on Deafness and Other Communication Disorders of America, the prevalence of Meniere’s disease is high in America and around 615,000 Americans are suffering from Meniere’s disease and the number of patients increasing every year. Massachusetts Eye and Ear (An international center for treatment and research and a teaching hospital of Harvard Medical School) reported that approximately 60,000 new cases of Meniere’s disease are diagnosed annually.
Get More Insights About Global Meniere's Disease Drug Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-menieres-disease-drug-market
Market Drivers
High prevalence of Meniere’s disease is driving the market growth
Increasing awareness of this disorder is another important factor for the market growth
Rising investment in the research & development for the treatments for this disease is expected to drive the market growth
Government initiative to increase awareness is elevating the market growth
Market Restraints
Lack of any approved drug or treatment option is restricting the market growth
Low healthcare expenditure in developing regions also acts as a market restraint
High cost of treatment for this disease can also hamper the market growth
Segmentation: Global Meniere's Disease Drug Market
By Type
Classic
Vestibular
Bilateral
By Mechanism of Action
Anti-Histamines
Benzodiazepines
Antinausea
Diuretics
Antibiotics
Steroids
Others
By Drugs Type
Meclizine
Diazepam
Prochlorperazine
Hydrochlorothiazide
Gentamicin
Dexamethasone
Others
By Devices type
Hearing Aid
Meniett device
By Treatment Type
Medications
Therapy or Hearing Aids
Surgery
By Route of Administration
Oral
Intravenous
Intratympanic
Others
By Distribution Channel
Online Pharmacy
Direct Tenders
Retailers
Others
By End-Users
Hospitals
Homecare
Specialty Clinics
Others
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
Italy
U.K.
France
Spain
Netherlands
Belgium
Switzerland
Turkey
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Singapore
Malaysia
Thailand
Indonesia
Philippines
Rest of Asia Pacific
South America
Brazil
Rest of South America
Middle East & Africa
South Africa
Rest of Middle East & Africa
Know more about this report https://www.databridgemarketresearch.com/reports/global-menieres-disease-drug-market
Key Developments in the Market
In June 2019, Otonomy Inc. is developing Otividex drug for the treatment of Meniere’s disease which is under Phase 3 clinical trial, in November 2017 Otonomy Inc announced that the AVERTS-2 trial, conducted in Europe, achieved its primary endpoint (p value = 0.029) and Otividex demonstrated clinically significant treatment benefit for patients
In May 2018, FDA approved IDE study for the treatment of Meniere’s disease and intractable vertigo. In this study simultaneously labyrinthectomy and cochlear implantation can be done in unilateral Meniere's disease which further assists in determining speech perception, localization and quality of life outcomes
Competitive Analysis:
Global Meniere’s disease drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Meniere’s disease drug market for Global Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
The key market players in the global Meniere’s disease drug market are Abbott, Otonomy Inc., WellSpring Pharmaceutical Corporation, Sound Pharmaceutical, Jubilant Cadista, Auris Medical, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Novartis AG, Abbott, Bayer AG, GlaxoSmithKline plc, Amneal Pharmaceuticals LLC., LUPIN, Sanofi, Solvay, XOMA and others.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-menieres-disease-drug-market
Browse Trending Related Reports @
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com